Summary
Researchers at the Paul Scherrer Institute PSI under the direction of Polina Isaikina have for the first time determined the three-dimensional molecular structure of human cone opsins in their dark state. Cone opsins are light-sensitive receptor proteins in the retina responsible for color vision, sharp vision, and the perception of rapid movements. The study, published in Science, combines cryo-electron microscopy, laser spectroscopy, and computational methods. The findings could open new therapeutic approaches for eye diseases such as color blindness and age-related macular degeneration (AMD).
People
- Polina Isaikina (Study Director, PSI Center for Life Sciences)
- Sarah L. Schmidt (First Author, Doctoral Candidate)
Topics
- Molecular biology of vision
- Cone opsins and photoreceptors
- Eye diseases and therapeutic development
- Structural biology and cryo-electron microscopy
Clarus Lead
This discovery addresses a long-standing puzzle in vision research: How can cone opsins convert light impulses into electrical signals in the blink of an eye? The answer lies in their molecular architecture – a network of internal "microswitches" that are already connected to intracellular signaling partners in their resting state. For millions of people with visual impairments – about five percent of the world's population suffers from color vision disorders – this structural understanding opens concrete starting points for targeted drug development and optogenetic therapies.
Detailed Summary
The human eye contains six to seven million cone cells per eye, densely packed in the fovea centralis. Three types of cone opsins enable color vision: L-cones respond to red light, M-cones to green, and S-cones to blue light. Their overlapping spectral sensitivities create the perception of thousands of colors. The key to speed lies in retinal, a light-sensitive molecule derived from vitamin A at the center of each opsin. When light transfers energy to the retinal, its shape changes and activates the photoreceptor – a process so fast that we can track moving objects with our eyes.
The researchers discovered structural differences between the opsins: The green-sensitive opsin has a relatively open retinal-binding pocket that permits rapid ligand exchange and even allows spontaneous activation in the dark. The blue-sensitive opsin, by contrast, has a more compact binding pocket with "closed doors" that requires higher-energy blue light. This structural adaptation explains the different spectral sensitivities. The findings could help understand mechanisms of eye diseases in which photoreceptors are lost or function improperly – particularly age-related macular degeneration, which can lead to blindness. In the long term, the researchers hope their results will advance the development of medications that stabilize cone opsins and slow vision loss.
Key Points
- For the first time, the three-dimensional structure of human cone opsins in the inactive state was successfully determined
- Cone opsins are designed for rapid signal transmission through an internal network of "microswitches"
- Structural differences between blue-, green-, and red-sensitive opsins explain their different activation thresholds
- The results open new therapeutic approaches for color blindness and age-related macular degeneration
Critical Questions
Evidence: Have the structural data been validated by independent research groups, or are they based exclusively on PSI measurements?
Source Quality: How reliable is cryo-electron microscopy in imaging dynamic proteins that can spontaneously activate even in the dark?
Generalizability: The study directly examined only blue- and green-sensitive opsins. To what extent can the results be transferred to the red-sensitive opsin, which was not directly investigated?
Causality: Do the structural differences (open versus closed binding pockets) actually show the cause of different activation thresholds, or are these merely correlations?
Feasibility: What realistic time horizon is assumed for the development of therapeutic applications – years or decades?
Conflicts of Interest: Are the researchers involved affiliated with biotech companies that could commercialize optogenetic therapies?
References
Primary Source: New Insights into Human Vision – Paul Scherrer Institute PSI, 25.06.2026
Scientific Publication: Schmidt, S. L., et al. (2026). Illuminating the molecular basis of human daylight vision. Science, 25.06.2026 (online). DOI: 10.1126/science.adz3624
Verification Status: ✓ 25.06.2026
This text was created with the support of an AI model. Editorial Responsibility: clarus.news | Fact-Check: 25.06.2026